Last reviewed · How we verify
2 g piracetam intravenous
Piracetam, a 2 g intravenous formulation developed by Kocaeli University, is currently marketed but lacks detailed revenue data and primary indication information. The key composition patent expires in 2028, providing a clear timeline for potential generic competition. The absence of key trial results and identified competitors poses a significant risk to assessing the drug's market performance and competitive landscape.
At a glance
| Generic name | 2 g piracetam intravenous |
|---|---|
| Sponsor | Kocaeli University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo (PHASE4)
- A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 2 g piracetam intravenous CI brief — competitive landscape report
- 2 g piracetam intravenous updates RSS · CI watch RSS
- Kocaeli University portfolio CI